Clinical Trials Directory

Trials / Completed

CompletedNCT02172339

The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects

The Pharmacokinetic, Safety and Tolerability of Tiotropium (4.8 mcg, Single i.v. Dose) in Outpatients With Renal Impairment in Comparison to Healthy Subjects (Open Label, Group Comparison, Two-center Study)

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
All
Age
40 Years – 70 Years
Healthy volunteers
Accepted

Summary

Study to investigate pharmacokinetics of a single i.v. dose of tiotropium (4.8 mcg) in patients with renal impairment in comparison to healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGTiotropium, solution ampoules

Timeline

Start date
1998-04-01
Primary completion
1998-12-01
First posted
2014-06-24
Last updated
2014-06-24

Source: ClinicalTrials.gov record NCT02172339. Inclusion in this directory is not an endorsement.

The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy (NCT02172339) · Clinical Trials Directory